Amir Gadit
About Amir Gadit
Amir Gadit is the Sr. Manager of Commercial Strategy and Forecasting for Myeloma at Bristol Myers Squibb, with a background in pharmacy and extensive experience in drug safety and risk management.
Company
Amir Gadit is currently employed at Bristol Myers Squibb, a leading global biopharmaceutical company, where he serves as the Sr. Manager for Commercial Strategy and Forecasting (Myeloma). This role commenced in January 2021.
Title
Amir Gadit's current title is Sr. Manager, Commercial Strategy and Forecasting (Myeloma) at Bristol Myers Squibb. In this role, he is involved in the strategic planning and forecasting specific to myeloma therapies.
Previous Experience
Before joining Bristol Myers Squibb, Amir Gadit worked at Celgene for several years. He held the position of Sr. Manager, R&D Portfolio Analytics from 2019 to 2020. Prior to that, he served in various roles in Global Drug Safety & Risk Management at Celgene from 2013 to 2018. Amir also has experience in medical communications and drug safety from his role at C3i Solutions, where he worked from 2011 to 2013. Additionally, he worked as a Staff Pharmacist at Healthsource Pharmacy in the Greater New York City Area from 2011 to 2013.
Education and Expertise
Amir Gadit earned his Master of Business Administration (MBA) with a focus on Finance from Rutgers Business School, attending from 2016 to 2019. He also holds a Doctor of Pharmacy (PharmD) from Saint John's University, where he studied from 2005 to 2011. His educational background provides a strong foundation in both business administration and pharmacy.
Background
Amir Gadit has a diverse professional background that spans drug safety, medical communications, and pharmacy. His combined experiences at C3i Solutions, Healthsource Pharmacy, and Celgene have equipped him with a comprehensive skill set in drug safety and risk management. In his current role at Bristol Myers Squibb, Amir leverages this expertise to manage commercial strategies and forecasting for myeloma therapies.